BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

Rhea-AI Summary

BioMarin (NASDAQ: BMRN) will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Wednesday, August 12, 2026, at 8:00AM ET. A live audio webcast and a time-limited archived replay will be accessible via the company’s investor website.

Market Reaction – BMRN

+5.85% $67.54

15m delay

+5.85% Vs previous close

$67.54 Last Price

$63.34 $67.69 Day Range

$13.07B Market Cap

0.9x Rel. Volume

Following this news, BMRN has gained 5.85%, reflecting a notable positive market reaction. Our momentum scanner has triggered 60 alerts so far, indicating high trading interest and price volatility. The stock is currently trading at $67.54.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

A prior +0.14% 24-hour reaction followed BioMarin's FDA acceptance announcement, providing a histori...

Analysis

A prior +0.14% 24-hour reaction followed BioMarin's FDA acceptance announcement, providing a historical reference for this scheduling notice. The release added presentation logistics rather than new clinical or financial data.

Key Figures

Conference edition: 46th annual Presentation date and time: August 12, 2026 at 8:00 AM ET Company founding year: 1997 +1 more

4 metrics

Conference edition 46th annual Canaccord Genuity Growth Conference

Presentation date and time August 12, 2026 at 8:00 AM ET Management presentation

Company founding year 1997 BioMarin company history

Commercial therapies nine commercial therapies Company description

Historical Context

5 past events · Latest: Jul 30 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 30	conference scheduling	Neutral	-1.3%	Announced second-quarter results conference call and webcast scheduled for August 6
Jul 27	research collaboration	Positive	+1.6%	Entered early research collaboration and exclusive license for ReNU syndrome medicine
Jul 13	FDA filing acceptance	Positive	+0.1%	FDA accepted VOXZOGO supplemental application and set February 28, 2027 action date
Jun 16	clinical data update	Positive	-0.9%	Reported three-year VOXZOGO data and early BMN 333 Phase 1 results
May 20	Phase 3 clinical data	Positive	+7.8%	Reported positive CANOPY-HCH-3 results with significant growth-velocity improvement

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BioMarin's recent news reactions were mixed, with three aligned reactions and two divergences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.

An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com. 

Contacts:
Investors	Media
Traci McCarty	Marni Kottle
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(650) 374-2803

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-at-the-canaccord-genuity-46th-annual-growth-conference-on-wednesday-august-12-2026-at-800am-et-in-boston-302844104.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When will BioMarin (BMRN) present at the Canaccord Genuity 46th Annual Growth Conference?

BioMarin will present on Wednesday, August 12, 2026, at 8:00AM ET. According to BioMarin, this presentation is part of the Canaccord Genuity 46th Annual Growth Conference held in Boston, focused on company updates for investors.

How can investors access the BioMarin (BMRN) webcast for the August 12, 2026 conference presentation?

Investors can access the live audio webcast at https://investors.biomarin.com/. According to BioMarin, an archived version of the remarks will also be available on the company’s website for a limited time following the conference.

Will a replay of BioMarin’s August 12, 2026 Canaccord Genuity conference presentation be available?

Yes, a replay will be available for a limited time. According to BioMarin, an archived version of the conference remarks can be accessed through the company’s website after the live presentation concludes.

Where is the Canaccord Genuity 46th Annual Growth Conference featuring BioMarin (BMRN) being held?

The conference featuring BioMarin’s presentation is being held in Boston. According to BioMarin, management will present on August 12, 2026, at 8:00AM ET, with online webcast access for remote investors.

What type of company is BioMarin (NASDAQ: BMRN) presenting at the August 2026 Canaccord Genuity conference?

BioMarin is a global rare disease biotechnology company focused on genetically defined conditions. According to BioMarin, it has nine commercial therapies and a strong clinical and preclinical pipeline, emphasizing innovation in genetic science and category-defining medicines.

Where can I find more information about BioMarin (BMRN) ahead of the August 12, 2026 conference?

More information is available at www.biomarin.com and the investor site. According to BioMarin, these sites provide background on its rare disease focus, commercial therapies, and pipeline ahead of the conference presentation.